Cargando…

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer

BACKGROUND: Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic g...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezvani, Hamid, Haghighi, Shirin, Ghobakhlou, Mehdi, Ataei, Elnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731017/
https://www.ncbi.nlm.nih.gov/pubmed/36505597
http://dx.doi.org/10.4103/jfmpc.jfmpc_1678_21
_version_ 1784845812454391808
author Rezvani, Hamid
Haghighi, Shirin
Ghobakhlou, Mehdi
Ataei, Elnaz
author_facet Rezvani, Hamid
Haghighi, Shirin
Ghobakhlou, Mehdi
Ataei, Elnaz
author_sort Rezvani, Hamid
collection PubMed
description BACKGROUND: Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer. METHODS AND MATERIALS: In this prospective cohort, 13 consecutive patients with metastatic gastric cancer attending Taleghani Hospital that underwent ramucirumab + folfiri therapy were enrolled, and the therapeutic response among them was determined. RESULTS: The results in this study demonstrated that initial therapeutic response was 92.3% and the Progression-free Survival (PFS) was 16.2 months (84.6%) (CI95%:13.2-19.3). The nine-month PFS was 69.2%. Total survival was 16.7 months (CI95%:13.5-19.9). CONCLUSION: Ultimately, according to the obtained results, it may be concluded that the therapeutic response to ramucirumab + folfiri in a patient with metastatic gastric cancer is good, and the use of this regimen is recommended.
format Online
Article
Text
id pubmed-9731017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-97310172022-12-09 Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer Rezvani, Hamid Haghighi, Shirin Ghobakhlou, Mehdi Ataei, Elnaz J Family Med Prim Care Original Article BACKGROUND: Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer. METHODS AND MATERIALS: In this prospective cohort, 13 consecutive patients with metastatic gastric cancer attending Taleghani Hospital that underwent ramucirumab + folfiri therapy were enrolled, and the therapeutic response among them was determined. RESULTS: The results in this study demonstrated that initial therapeutic response was 92.3% and the Progression-free Survival (PFS) was 16.2 months (84.6%) (CI95%:13.2-19.3). The nine-month PFS was 69.2%. Total survival was 16.7 months (CI95%:13.5-19.9). CONCLUSION: Ultimately, according to the obtained results, it may be concluded that the therapeutic response to ramucirumab + folfiri in a patient with metastatic gastric cancer is good, and the use of this regimen is recommended. Wolters Kluwer - Medknow 2022-09 2022-10-14 /pmc/articles/PMC9731017/ /pubmed/36505597 http://dx.doi.org/10.4103/jfmpc.jfmpc_1678_21 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Rezvani, Hamid
Haghighi, Shirin
Ghobakhlou, Mehdi
Ataei, Elnaz
Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title_full Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title_fullStr Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title_full_unstemmed Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title_short Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
title_sort therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731017/
https://www.ncbi.nlm.nih.gov/pubmed/36505597
http://dx.doi.org/10.4103/jfmpc.jfmpc_1678_21
work_keys_str_mv AT rezvanihamid therapeuticresponsetoramucirumabfolfiriinpatientswithmetastaticgastriccancer
AT haghighishirin therapeuticresponsetoramucirumabfolfiriinpatientswithmetastaticgastriccancer
AT ghobakhloumehdi therapeuticresponsetoramucirumabfolfiriinpatientswithmetastaticgastriccancer
AT ataeielnaz therapeuticresponsetoramucirumabfolfiriinpatientswithmetastaticgastriccancer